We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44 ± 3 vs 36 ± 3%, P ¼ 0.023; leukemia-free survival (LFS): 47 ± 3 vs 36 ± 4%, P ¼ 0.038; and cumulative incidence of relapse (CIR): 37 ± 3 vs 47 ± 4%, P ¼ :0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59±4%, LFS:59±4% and CIR: 26±4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48 ± 5%, LFS:41 ± 4% and CIR: 45 ± 4%); and Group 2 (WT1 4170.5 copies, 71 patients, OS: 23 ± 6%, LFS: 19 ± 7% and CIR: 68 ± 8%) (Po0.001). Post-intensification samples distinguished three groups: patients with WT1 4100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 o10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30±7%, 59±4%, 72±5%), LFS (24±7%, 46 ± 4%, 65 ± 5%) and relapse probability (CIR 72 ± 7%, 45 ± 4%, 25 ± 5%), all Po0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML.
INTRODUCTION
Minimal residual disease (MRD) analysis based on quantitative PCR of common fusion or mutated genes is gaining acceptance as a risk stratification tool and as a measure of impending relapse in acute myeloid leukemia (AML). Knowledge of the genetic mechanisms underlying leukemic transformation has markedly enlarged the available lesions which could be used to follow AML. However, most AML cases lack validated and standardized genetic targets and should be followed by multiparametric flow cytometry (MPFC), which is technically demanding. 1 WT1 is a transcription factor that is overexpressed in most de novo AML cases and in other myeloproliferative neoplasms. [2] [3] [4] It is essential in mesenchymal tissue maintenance through the Wnt4 pathway, 5 and it is expressed in a small percentage of bone marrow CD34 þ cells. It is upregulated in early myeloid progenitors, and is downregulated at later stages of differentiation. 6 Studies in mice have shown that WT1 overexpression is required for leukemogenesis. [6] [7] [8] In human leukemias, WT1 is mutated in 10% of AML and in 12-13% of T-cell lineage ALL. 9, 10 Despite these findings, it is not fully understood how WT1 overexpression and mutations contribute to the leukemic phenotype. WT1 expression monitoring is becoming an almost universal target to follow de novo AML. [11] [12] [13] [14] [15] [16] Its expression in myeloid malignancies is upregulated in parallel with the blast percentage. WT1 determination has recently been standardized as a result of a European Leukemia Net initiative. 12 Raised WT1 levels at diagnosis and post-induction have been associated with a poor outcome in de novo adult and pediatric AML. WT1 levels have also been used recently as a leukemia relapse predictor in bone marrowtransplanted patients. 17 WT1 levels in peripheral blood are much lower than those in bone marrow. In line with this finding, earlier reports have shown that best results in establishing clinical predictions are obtained when post-induction peripheral blood is used. 18 Most currently applied MRD studies, however, are based on routinely obtained bone marrow samples. As there is no consensus on clinically relevant thresholds to guide clinical decisions and to determine the optimal time-point of WT1 assessment in large multi-center trials, WT1 quantitation has not yet gained widespread use, despite all its potential advantages. The fact that some AML show normal WT1 levels at diagnosis could also be partly responsible. [2] [3] [4] 12 To investigate the prognostic impact of the normalized bone marrow WT1 levels at diagnosis, post-induction and post-intensification, we analyzed a consecutive series of de novo AML patients from CETLAM group trials using the standardized ELN method. At the same time, we investigated whether the mutational status of WT1 had some influence on WT1 levels or on the clinical outcome.
PATIENTS AND METHODS

Molecular methods
Available bone marrow samples at diagnosis (584 patients), post-induction (365 patients) and post-consolidation (287 patients) were obtained in each participating institution and sent to the CETLAM repository center at the Hospital de la Santa Creu i Sant Pau in Barcelona for complete immunophenotype and molecular analyses. Diagnostic samples from all patients were analyzed for mutations in the NPM1, FLT3, CEBPA, MLL and WT1 genes using well-established protocols. 13, 19 Mononuclear cells were separated using Lymphoprep (Axis-Shield, Oslo, Norway) and lysed with Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. One microgram of RNA was reverse transcribed to cDNA in a total reaction volume of 20 ml containing Cl 2 Mg 5 mM, 10Â Buffer, DTT 10 mM, dNTP's 10 mM each, random hexamers 15 mM, RNAsin 20 units (Promega, Fitchburg, MA, USA) and 200 units of MMLV enzyme (Applied Biosystems, Foster City, CA, USA). Samples were incubated for 10 min at 20 1C, 45 min at 42 1C and 3 min at 99 1C, followed by 10 min at 4 1C.WT1 expression levels were determined by real-time quantitative PCR (RQ-PCR) in an ABI PRISM 7500 Genetic Analyzer (Applied Biosystems), using the primers and conditions described by the ELN group. 12 For WT1 copy-number titration, the Ipsogen (Marseilles, France) plasmid was used. Abl was used as control gene. Results were expressed as copies and four normal bone marrow samples were used as test controls.
Treatment protocol
Patients were treated between 2004 and 2011 according to the CETLAM AML-03 protocol trial. 19 Informed consent was obtained from each patient. Adults up to 70 years of age received induction chemotherapy with idarubicin, intermediate-dose cytarabine and etoposide, followed by consolidation with mitoxantrone and intermediate-dose ara-C. Subsequently, patients with favorable cytogenetics at diagnosis received one cycle of high-dose cytarabine. Those with a normal karytotype and needing a single course to achieve complete remission (CR) were treated with autologous transplantation. G-CSF priming was used during induction and consolidation. Patients with favorable cytogenetics and high leukocyte counts at diagnosis were treated with autologous transplantation instead of high-dose cytarabine. A favorable genotype was defined as the presence of NPM1 or biallelic CEBPA mutations associated with no FLT3 mutations. Patients with a normal karyotype but an adverse molecular profile (FLT3 mutations or MLL rearrangements including partial tandem duplications assessed by long-distance PCR) were allocated to the treatment for unfavorable cases; this included allogeneic transplantation from an HLA-identical donor (related or unrelated) or autologous transplant after in vivo purging with 3 mg/m 2 IV of Mylotarg (Pfizer, New York, NY, USA). Of note, patients X50 years old with an allogeneic donor received reduced-intensity conditioning with fludarabine and busulfan.
Statistical methods
Overall survival (OS) was measured from the date of enrollment until the date of death. Leukemia-free survival (LFS) for patients who achieved a CR was calculated from the date of CR to that of relapse or death. OS and LFS were plotted by the Kaplan-Meier method; differences between curves were analyzed by the log-rank test. The probability of relapse was calculated using cumulative incidence estimates and taking into account the competing risk of death in remission. After exploratory univariate comparisons, multivariate analyses were performed, including the variables with P-value o0.15. The regression models used were COX and Fine and Gray test.
The threshold values were established by selecting the most accurate values by a nonparametric receiver-operating characteristics analysis, taking into account the maximum ratio sensitivity-specificity. The end point for the threshold was death and relapse. This approach was applied following the REMARK guidelines. 
RESULTS
WT1 levels in de novo AML samples at diagnosis
A bone marrow RNA sample at diagnosis to perform WT1 quantitation was available in 584 de novo AML cases enrolled in the CETLAM protocol. The characteristics of this group were equivalent to the whole CETLAM series ( Table 1 ). The WT1 RNA results were expressed as copies. The receiver-operating characteristics analysis revealed a 5065 cutoff value at diagnosis, which was statistically significant in terms of sensitivity and specificity. Using this value, cases with WT1 levels above 5065 copies had a significantly worse outcome in terms of OS, LFS and probability of relapse (OS: 44 ± 3 vs 36 ± 3%, P ¼ 0.023; LFS: 47 ± 3 vs 36±4%, P ¼ 0.038 and CIR 37±3 vs 47±4%, P ¼ 0.043; Figure 1 ). When investigating whether the adverse prognosis was linked to any clinical and/or biological variable, we found a statistically significant association between raised WT1 levels and marked leukocytosis. The median leukocyte count in cases with WT1 levels below 5065 was 9.4 Â 10 6 (0.23-400), whereas in those with more than 5065 WT1 copies, it was 49.81 Â 10 6 (0.7-325; Po0.001).
Normal bone marrow samples had a mean WT1 value of 200 copies. One hundred and six (18%) AML patients had WT1 levels below 200 copies at diagnosis. When these cases are excluded, the observed OS, LFS and CIR at diagnosis were similar to the whole series (Supplementary Figure 1) . Based on these findings, we assumed that cases with the highest leukemic burden assessed by WT1 copy-number quantitation had more leukocytes and, accordingly, a bad prognosis.
Post-induction WT1 levels WT1 post-induction levels were obtained in 365 patients. The characteristics of these cases are detailed in Table 1 .
As regards the post-induction results, three groups were established: Group 0 (134 patients) with WT1 levels between 0 and 17.5 copies, Group 1 (160 patients) with WT1 values ranging from 17.6 to 170.5 copies, and Group 2 (71 patients) with WT1 levels after induction greater than 170.5 copies. These groups showed statistically significant differences (Po0.001) in terms of OS: Group 0: 59±4 months, Group 1: 48±5 months and Group 2: 23±6 months. LFS was also statistically different: Group 0: 59 ± 4, Group 1: 41 ± 4 and Group 2: 19 ± 7 (all Po0.001). Lastly, CIR was markedly different between the three groups: Group 0: 26±4, Group 1: 45±4, and Group 2: 68±8(Po0.001) ( Figure 2 ). Twenty-six out of the 35 cases failing to achieve CR after induction were in the Group 2 (WT14170.5 copies) (Po0.001).
Based on these results, we concluded that patients with WT1 post-induction levels greater than 170.5 corresponded to induction failures or patients with a very high risk of relapse. These results were even more evident when cases with WT1 levels below 200 copies at diagnosis were excluded from the analysis (Supplementary Figure 2) . Post-intensification WT1 levels Post-intensification WT1 levels were available from 287 patients. Table 1 shows the clinical and biological characteristics of this subgroup compared with the whole CETLAM series.
Receiver-operating characteristics studies performed on the available data identified three prognostically relevant groups: cases with WT1 levels greater than 100 copies (n: 47 patients, 16%), an intermediate group with WT1 levels between 10 and 100 copies (n: 148 patients, 52%), and a third group with WT1 levels of o10 copies (n: 92 patients, 32%). Outcomes in these three groups showed statistically significant differences in terms of OS (72±5, 59±4, 30±7, Po0.001), LFS (65±5, 46±4, 24±7, Po0.001) and relapse probability (CIR 25 ± 5, 45 ± 4, 72 ± 7, Po0.001) (Figure 3) . Cases with the lowest WT1 level had a very good prognosis, making WT1 reduction to values of o10 after intensification a good end-point target to assess the efficacy of chemotherapeutic regimens in de novo AML. Again, when the subgroup of patients with WT1 levels o200 copies at diagnosis was excluded from the analysis, differences between the groups in OS, LFS and CIR were more evident (Supplementary Figure 3) .
Multivariate analysis revealed an independent prognostic value of post-induction and post-consolidation WT1 levels Univariate analysis disclosed statistically significant association in terms of OS, LFS and CIR with age, cytogenetic classification according to the MRC criteria, absence of favorable genotype defined by FLT3 germ line þ NPM or biallelic CEBPA mutation, WT1 levels at diagnosis, post-induction and post-intensification (Table 2 ). When multivariate analysis was performed, age, favorable genotype and WT1 levels post-intensification remained as independent prognostic factors in terms of LFS and CIR ( Table 2 ). The entire database was randomly split into two groups and the currently employed thresholds, post-induction and postintensification, retained its statistical significance in both groups. These results imply that age and a relatively simple genetic characterization (NPM, CEBPA mutations and post-intensification WT1 levels) could provide relevant prognostic stratification in AML trials 21 (Supplementary Tables 1, 2 , 3 and 4).
WT1 expression in WT1-mutated AML Mutations in exons 7 and 9 of WT1 were investigated in 420 samples with DNA available at diagnosis. We detected 41 cases with a WT1 mutation (10%). Cases with mutated WT1 had WT1 mean levels of 5732.71 copies compared with 9274.34 copies for cases with non-mutated WT1 (P ¼ ns) There were no statistically significant differences between cases with mutation and wild-type WT1 in terms of WT1 levels at diagnosis (fewer or more than 5065 copies) ( Table 3) . We did not find any prognostic impact in terms of OS, LFS or CIR based on WT1 mutations. WT1 mutations were significantly associated with age, FLT3-ITD and CEBPA mutations (Table 3) .
DISCUSSION
In this manuscript we have shown that bone marrow WT1 levels provide prognostically relevant information at diagnosis, post-induction and post-intensification time-points in de novo AML cases. These results were obtained using a well-standardized protocol that takes advantage of commercially available plasmid reagents (Ipsogen). 12 Furthermore, the most favorable WT1 level after intensification (10 copies) was in the same range as those obtained using chimeric targets in core-binding factor AML. 22 This subgroup of patients with very low WT1 levels had an excellent outcome. This could make AML monitoring much easier and provide a common theoretical target of MRD for all AML cases enrolled in clinical protocols. Based on our findings, we hypothesize that normal WT1 values may not be the same in normal bone marrow as in bone marrow of patients with acute leukemia treated with chemotherapy or BMT. 23, 24 In the latter cases, the physiologic levels may be lower than in non-treated normal bone marrow. This should be taken into consideration when analyzing AML cohorts, given that there are B200 copies of WT1 in normal bone marrow. These values may be even higher in younger cases. 13 The main limitation of this study is therefore that our findings need to be confirmed in other series, specially with regard to the clinically relevant post-intensification thresholds in bone marrow or in peripheral blood. It should also be confirmed whether other standardized methods of WT1 quantitation are useful in clinical prediction and whether our findings can be reproduced in pediatric patients.
Current AML treatment includes induction chemotherapy and intensive consolidation. Depending on multiple genetic and biologic data at diagnosis, patients receive additional treatment, ranging from allogeneic BMT to less-intensive chemotherapy. The goal of these treatments is to kill leukemic cells, specially those with stem-cell behavior. The probability of relapse in a given patient is directly proportional to the amount of MRD for each time-point analyzed. The need to detect small amounts of neoplastic cells and/ or leukemic nucleic acids mixed in a non-neoplastic background has prompted the development of sensitive techniques to pinpoint leukemic remnants. The two most commonly used techniques are MPFC and RT-PCR based methods (real-time PCR). 1, 25 The main advantages of MPFC are speed, high sensitivity and potential application to most AML cases. However, MPFC standardization has not been fully developed, 26 and it is highly dependent on an accurate antigenic characterization at diagnosis. MPFC also requires optimized acquisition protocols and some degree of expertise to analyze the results. In contrast, RQ-PCR methods are very sensitive, rapid and well standardized. However, they are dependent on a suitable target such as those provided by the chimeric gene fusions that are common in some types of leukemias. In this respect, WT1 levels are becoming a universal surrogate marker of leukemic persistence.
Using a competitive PCR, Bergmann et al. 27 showed an association of WT1 levels at diagnosis with age, FAB subtype, imunophenotype (CD34 and CD33 expression), karyotype, and long-term survival. In line with these findings, Barragan et al. 28 found an association between bone marrow WT1 levels at diagnosis and prognosis in adult AML patients. High GATA2 and WT1 levels at diagnosis have also been associated with an adverse outcome in pediatric AML. 29 These findings are in agreement with the report by Furuhata et al. 30 who demonstrated that GATA1 and GATA2 binding to 3 0 enhancer regions of WT1 is essential for its transcription. Gaur et al. 31 analyzed WT1 levels in APL and found an association between polymorphisms at the SNP rs16754 and WT1 levels. 31 Shimada et al. 32 did not detect prognostic relevant correlations between WT1 levels at diagnosis in 158 pediatric AML cases. In contrast, these authors found an adverse prognostic impact of raised WT1 levels in 74 post-induction samples. Lapillone et al. 33 analyzed 92 pediatric AML patients at diagnosis and follow-up. WT1 at diagnosis was higher in favorable cytogenetics and lower in the M5-FAB subtype, 11q23 rearrangements and infant leukemias. They also found that Prognostic value of WT1 levels in AMLraised post-induction WT1 levels had an adverse prognostic impact. Based on our results, the adverse prognostic impact of raised WT1 levels at diagnosis may be attributed to an association with higher leukocyte counts. Using a competitive RT-PCR with Abl as control gene, Garg et al. 34 found a link between increased post-induction in bone marrow and peripheral blood WT1 levels and outcome. Cilloni et al. 18 reported findings similar to ours. When these authors analyzed the peripheral blood of postinduction AML samples, those cases with 420 copies relapsed. However, these authors pointed out that approximately half of the patients who reached normal WT1 levels relapsed, suggesting that the post-induction thresholds, also in peripheral blood, should be refined. These findings are in line with our results. We were able to establish prognostic subgroups even in cases with WT1 levels considered normal until now. Pozzi et al. 17 analyzed the prognostic value of bone marrow WT1 levels using the ELN protocol in the bone marrow transplantation setting. They found that patients with WT1 levels exceeding 100 copies had higher probabilities of relapse than those with levels below this value. They also took clinical decisions (donor lymphocyte infusions or immunosuppression discontinuation) when the patients reached 180 copies. However, using this threshold the probability of leukemia relapse did not decrease, suggesting that the clinically relevant threshold should be much lower. Rossi et al. 35 performed MRD studies using both flow cytometry and WT1 quantitation in a small series of AML patients. These authors found that WT1 levels greater than 90 copies were associated with a poor prognosis. However, all the available information on the prognostic value of WT1 quantitation in AML was obtained from small cohorts of patients or by using a non-standardized method.
The ELN is not the only standardization initiative. Recently, Willasch et al. 36 reported another standardized WT1 assay. Using this method, these authors showed that pediatric AML with WT1 mutations had significantly higher WT1 levels than non-mutated cases. We were unable to find this association in our adult AML cases.
In this work, we found a 10% frequency of WT1 mutations and these cases did not have an adverse outcome. This may be explained by the counterbalanced effects of FLT3-ITD and CEBPA mutations which were significantly associated with WT1 mutations. Other groups have reported that WT1 mutations were associated with FLT3 mutations and a poor prognosis, linked to a failure to achieve CR. 9, 10 Somatic WT1 mutations are typically located in exons 7 and 9 (zinc-finger regions). Frameshift mutations in exon 7 result in a truncation of the WT1 protein, excluding the four zinc-finger domains, and cause a loss in the DNA-binding capacity. Furthermore, WT1-mutated cases did not show different WT1 levels compared with those cases without WT1 mutation.
In conclusion, raised post-induction and post-intensification WT1 levels are powerful stratification markers in adult de novo AML patients. We were able to identify induction failures based on bone marrow WT1 levels (4170.5 copies). Patients with very low WT1 levels post-intensification (o10 copies) had an excellent outcome, specially if they had also a favorable genotype. Bone marrow WT1 quantitation using the ELN method is a useful MRD tool that can be easily applied to all AML cases. 
